Table 2.
Preoperative cardiac medications, revascularization therapy, type of vascular disease, and incidence of MACE among the study cohorts
| Preoperative cardiac medications | |
|---|---|
| β-blockers | 114 (81%) |
| Antiplatelets | 138 (98%) |
| Statins | 121 (86%) |
| Nitrates | 25 (18%) |
| Antiarrhythmic drugs | 4 (3%) |
|
| |
| Preoperative revascularization therapy | |
|
| |
| Percutaneous coronary intervention | 24 (17%) |
| Coronary artery bypass grafting | 16 (11%) |
|
| |
| Type of vascular disease | |
|
| |
| TAAA type II | 5 (3%) |
| TAAA type III | 10 (7%) |
| TAAA type IV | 53 (38%) |
| TAAA type V | 32 (23%) |
| Aortoiliac-occlusive disease | 41 (29%) |
|
| |
| Incidence of MACE | |
|
| |
| Perioperative myocardial infarction | 5 (3.6%) |
| Hemodynamically significant arrhythmias | 6 (4%) |
| Intraoperative irreversible hypotension | 4 (3%) |
| Sudden cardiac death | 1 (0.7%) |
Values are expressed as numbers (proportion). TAAA, thoracoabdominal aortic aneurysm.